$CYCN
Cyclerion Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063023 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $0.00 $0.00 $608.0K
YoY Change -100.0% 14.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.771M $2.130M $3.506M
YoY Change -49.49% -39.57% -20.55%
% of Gross Profit
Research & Development $30.00K $580.0K $4.450M
YoY Change -99.33% -91.81% -57.45%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $1.795M $2.400M $7.956M
YoY Change -77.44% -77.37% -46.5%
Operating Profit -$6.015M
YoY Change -43.29%
Interest Expense $101.0K $110.0K $132.0K
YoY Change -23.48% -0.9% -13300.0%
% of Operating Profit
Other Income/Expense, Net $107.0K
YoY Change -3.6%
Pretax Income -$1.694M -$5.910M -$7.216M
YoY Change -76.52% -43.69% -33.03%
Income Tax
% Of Pretax Income
Net Earnings -$1.694M $7.566M -$7.216M
YoY Change -76.52% -172.08% -33.03%
Net Earnings / Revenue -1186.84%
Basic Earnings Per Share $3.11
Diluted Earnings Per Share -$0.69 $2.72 -$0.17
COMMON SHARES
Basic Shares Outstanding 2.445M 2.411M 43.49M
Diluted Shares Outstanding 2.786M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.571M $9.100M $13.38M
YoY Change -43.42% -55.4% -75.2%
Cash & Equivalents $7.571M $9.108M $13.38M
Short-Term Investments
Other Short-Term Assets $11.00K $30.00K $537.0K
YoY Change -97.95% -93.85% 14.74%
Inventory
Prepaid Expenses $442.0K $726.0K $805.0K
Receivables $0.00 $0.00 $96.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.024M $9.864M $14.82M
YoY Change -45.86% -54.45% -73.28%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.350M $5.400M
YoY Change
Other Assets $0.00 $0.00 $2.041M
YoY Change -100.0% -100.0% -15.21%
Total Long-Term Assets $5.350M $5.350M $3.259M
YoY Change 64.16% 57.49% -15.88%
TOTAL ASSETS
Total Short-Term Assets $8.024M $9.864M $14.82M
Total Long-Term Assets $5.350M $5.350M $3.259M
Total Assets $13.37M $15.21M $18.08M
YoY Change -26.02% -39.27% -69.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.198M $814.0K $2.970M
YoY Change -59.66% -50.52% 62.47%
Accrued Expenses $786.0K $1.400M $4.589M
YoY Change -82.87% -79.18% -47.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $3.500M
YoY Change -100.0% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.086M $2.341M $7.627M
YoY Change -72.65% -72.55% -31.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.086M $2.341M $7.627M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.086M $2.300M $7.627M
YoY Change -72.65% -73.03% -31.2%
SHAREHOLDERS EQUITY
Retained Earnings -$264.4M -$262.7M -$259.2M
YoY Change 2.01% 4.28% 20.52%
Common Stock $275.7M $275.6M $269.6M
YoY Change 2.26% 2.65% 2.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.29M $12.87M $10.45M
YoY Change
Total Liabilities & Shareholders Equity $13.37M $15.21M $18.08M
YoY Change -26.02% -39.27% -69.53%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$1.694M $7.566M -$7.216M
YoY Change -76.52% -172.08% -33.03%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$1.541M -$6.930M -$7.043M
YoY Change -78.12% -30.11% -18.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.000K $10.40M $0.00
YoY Change
Cash From Investing Activities $2.000K $10.40M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.000K 0.000 12.00K
YoY Change -66.67% -85.88%
NET CHANGE
Cash From Operating Activities -1.541M -6.930M -7.043M
Cash From Investing Activities 2.000K 10.40M 0.000
Cash From Financing Activities 4.000K 0.000 12.00K
Net Change In Cash -1.541M 3.470M -7.031M
YoY Change -78.08% -135.0% -17.72%
FREE CASH FLOW
Cash From Operating Activities -$1.541M -$6.930M -$7.043M
Capital Expenditures $0.00
Free Cash Flow -$7.043M
YoY Change -18.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001755237
us-gaap Defined Contribution Plan Type Extensible List
DefinedContributionPlanTypeExtensibleList
http://fasb.org/us-gaap/2023#QualifiedPlanMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38787
dei Entity Registrant Name
EntityRegistrantName
CYCLERION THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1895370
dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street
dei Entity Address Address Line2
EntityAddressAddressLine2
18th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
327-8778
dei Security12b Title
Security12bTitle
Common Stock, no par value
dei Trading Symbol
TradingSymbol
CYCN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.41
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259154000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
12873000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10452000
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2445096
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9108000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13382000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
96000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
726000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
805000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
30000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
537000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
9864000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14820000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1218000
CY2023Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
5350000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
0
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2041000
CY2023Q3 us-gaap Assets
Assets
15214000
CY2022Q4 us-gaap Assets
Assets
18079000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
814000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2970000
CY2023Q3 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
362000
CY2022Q4 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2275000
CY2023Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
1165000
CY2022Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2382000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2341000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7627000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2445096
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2445096
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2175936
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2175936
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
275614000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
269626000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262723000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15214000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18079000
CY2023Q3 cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
0
CY2022Q3 cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
0
cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
0
cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
297000
CY2023Q3 us-gaap Revenues
Revenues
0
CY2022Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
297000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
580000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1414000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1491000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4803000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2131000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3104000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6361000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9579000
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3304000
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3304000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6015000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4518000
us-gaap Operating Expenses
OperatingExpenses
11156000
us-gaap Operating Expenses
OperatingExpenses
14382000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6015000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4518000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11156000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14085000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
111000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
257000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
162000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5908000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-4407000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-10899000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13923000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
13474000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6089000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
7330000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-22939000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
us-gaap Net Income Loss
NetIncomeLoss
-3569000
us-gaap Net Income Loss
NetIncomeLoss
-36862000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.43
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.03
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.74
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
5.53
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.8
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
3.19
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-10.56
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.11
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.96
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.12
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.74
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.41
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.84
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.8
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
3.19
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-10.56
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.72
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.96
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2435000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2174000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2299000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2173000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2786000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2174000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2299000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2173000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
us-gaap Net Income Loss
NetIncomeLoss
-3569000
us-gaap Net Income Loss
NetIncomeLoss
-36862000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
7564000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10499000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3567000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36867000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48246000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12978000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1476000
CY2022Q1 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
291000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37034000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13388000
CY2022Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
17000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1410000
CY2022Q2 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
289000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25361000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1372000
CY2022Q3 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
290000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16524000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10452000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6954000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
416000
CY2023Q1 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
10000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3925000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4181000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1953000
CY2023Q2 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3047000
CY2023Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
24000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
373000
CY2023Q2 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
6000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5150000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
CY2023Q3 cycn Share Based Compensation Expense Related To Issuance Of Stock Options And Rsus To Employees
ShareBasedCompensationExpenseRelatedToIssuanceOfStockOptionsAndRsusToEmployees
154000
CY2023Q3 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
5000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
12873000
us-gaap Profit Loss
ProfitLoss
-3569000
us-gaap Profit Loss
ProfitLoss
-36862000
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
15752000
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3304000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Share Based Compensation
ShareBasedCompensation
964000
us-gaap Share Based Compensation
ShareBasedCompensation
5128000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-96000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
127000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-79000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-392000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-140000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
20000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-107000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-138000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-213000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-274000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2157000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-183000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-1912000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-2037000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1217000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-336000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19704000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33568000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
10402000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10402000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
24000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
17000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5024000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4274000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13382000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53961000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9108000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20405000
cycn Non Cash Gain On Disposal Of Discontinued Operations
NonCashGainOnDisposalOfDiscontinuedOperations
5350000
cycn Non Cash Gain On Disposal Of Discontinued Operations
NonCashGainOnDisposalOfDiscontinuedOperations
0
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
8000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2400000
CY2023Q1 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
5000000
CY2020Q3 cycn Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock
CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock
0.03
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
3353059000
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP") requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments, and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, impairment of long-lived assets, valuation procedures for right-of-use ("ROU") assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Settlement Of Asset Retirement Obligations Through Noncash Payments Amount
SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount
8000000
cycn Settlement Of Asset Retirement Obligations Through Noncash Payments Amount Reimbursement
SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmountReimbursement
2402000
us-gaap Transfer To Investments
TransferToInvestments
5350000
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
15752000
cycn Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset Net
ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAssetNet
0
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
15752000
CY2023Q3 cycn Closing Cost Sale Of Program Assets
ClosingCostSaleOfProgramAssets
1300000
cycn Closing Cost Sale Of Program Assets
ClosingCostSaleOfProgramAssets
1300000
CY2023Q3 cycn Transaction Costs Sale Of Program Assets
TransactionCostsSaleOfProgramAssets
200000
cycn Transaction Costs Sale Of Program Assets
TransactionCostsSaleOfProgramAssets
900000
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
8000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2400000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
126000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2181000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2181000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
238000
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
14000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
246000
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
17000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
186000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
676000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
835000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
300000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
809000
CY2023Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
158000
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
68000
CY2023Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
1165000
CY2022Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2382000
CY2020Q3 cycn Rentable Square Feet Terminated From Lease Agreement
RentableSquareFeetTerminatedFromLeaseAgreement
15700
CY2023Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Rooms
SubleaseTerminationAgreementEstimatedFairValueOfRooms
1500000
CY2023Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Services
SubleaseTerminationAgreementEstimatedFairValueOfServices
2900000
cycn Prepaid Rooms Balance Related To Other Assets
PrepaidRoomsBalanceRelatedToOtherAssets
1400000
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y10M17D
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
3300000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
3300000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
159000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1662000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
964000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5128000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11250
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.2
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y6M14D
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5908000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-4407000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-10899000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13923000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
13474000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6089000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
7330000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-22939000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
us-gaap Net Income Loss
NetIncomeLoss
-3569000
us-gaap Net Income Loss
NetIncomeLoss
-36862000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2435000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2174000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2299000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2173000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2786000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2174000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2299000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2173000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.43
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.03
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.74
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.41
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
5.53
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.8
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
3.19
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-10.56
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.11
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.96
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.12
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.74
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.41
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.84
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.8
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
3.19
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-10.56
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.72
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.96
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
351037
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
320107000
CY2022Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
423290000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
671144000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
423290000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
cycn Defined Contribution Plan Employer Matching Contribution Maximum
DefinedContributionPlanEmployerMatchingContributionMaximum
6000
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
809000
us-gaap Restructuring Charges
RestructuringCharges
-565000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1074000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
300000
cycn Ptc Grant Award
PtcGrantAward
2000000
cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
100000
CY2023Q3 cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
100000
cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
700000
CY2022Q3 cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
0

Files In Submission

Name View Source Status
cycn-20230930_cal.xml Edgar Link unprocessable
cycn-20230930_def.xml Edgar Link unprocessable
0000950170-23-063023-index-headers.html Edgar Link pending
0000950170-23-063023-index.html Edgar Link pending
0000950170-23-063023.txt Edgar Link pending
0000950170-23-063023-xbrl.zip Edgar Link pending
cycn-20230930.htm Edgar Link pending
cycn-20230930.xsd Edgar Link pending
cycn-ex31_1.htm Edgar Link pending
cycn-ex31_2.htm Edgar Link pending
cycn-ex32_1.htm Edgar Link pending
cycn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
cycn-20230930_lab.xml Edgar Link unprocessable
cycn-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cycn-20230930_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending